I continue to accept the dividends and (with them) buy more GSK. It compounds nicely ....;0) |
I'm sure many LTH's share your frustrations. What's peculiar now though is that GSK is not in bad shape with many approvals predicted for the next couple of years. However, the sentiment is very poor right now and this has been a feature for most of GSKs (old and new) existence. It's partly been of their own making as some good news has almost invariably been followed by bad many times and this has stalled momentum. |
If I were investing for capital growth then GSK which I've held for a very long time would be an utter crock. In fact the only reason my combined GSK/HLN holding is showing a small profit over my original cost of old GSK all those years ago is because HLN has boomed, up 51% on its allocated cost in the demerger, whilst new GSK is making a loss.
But I'm not a growth player, I'm an income investor and usually hold long term so don't trade much. However the income situation is not too attractive either because the total income from GSK+HLN is well below the 80p old GSK was paying pre-demerger. And even that 80p had been frozen for several years.
Not bad enough to dump but disappointing after decades. Still, that's the point of a diversified port where inevitably some sectors will do better than others but the essential trade-off is that risks are spread. |
1500-1600 would be pleasing. |
1800 by Christmas seems way too high in my opinion but let's hope so.
1500 would be ok with me and I agree it's been way oversold. Chasing it down is something I have been doing for a couple of months and 1410 as it stands gets me into profit.
I will continue to add on any dips as it feels like it's finally waking up again.
Good luck all 👍🏻 |
IF the pattern repeats the share seems to wobble along since 2012 between 1300-1800, so we could be due an upturn in the trend now.. :o) |
Yes it is on the up after the crazy overselling |
Momentum changing here now.. |
I think it will climb back to £18 by Christmas |
US. UK price target £9.Joking but.. it feels that way with this stock sometimes.. |
US or UK listing? |
Berenberg cuts target price to 1600p from 1820p |
Now going down so it should show thumbs down ? |
Every year I wonder why they don't do tomorrow the other way round??
Good luck all 👍🏻 |
United States stock markets will be closed on Thursday, Nov. 28 and will close early on Friday, Nov. 29 in observance of the Thanksgiving holiday. |
Took advantage of the dip this afternoon and decided to increase my holding a bit. I can't see this not doing well and the dividend is good |
And there's more ......
GSK plc (LSE/NYSE: GSK) today announced that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended for use a single-vial, fully liquid presentation of Menveo (Meningococcal Group A, C, W-135 and Y conjugate vaccine, MenACWY vaccine) to help protect against invasive meningococcal disease (IMD) caused by bacterial groups A, C, W, and Y. |
I assume we are talking about the US listing share price |
I preferred the 2610p ..........;0) |
Bernstein cuts target price to 2355p from 2610p |
That's what I thought , but no impact on today |
Nice late trades |
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
· Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy, including overall survival in DREAMM-7
· If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
· Sixth major regulatory filing acceptance this year for belantamab mafodotin combinations in this indication |
No rush await the inevitable dip. |
More good news ....
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
· First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions
· RSV infections can exacerbate these underlying health conditions and lead to severe outcomes, such as pneumonia, hospitalisation and death.
· 35 countries, including the US, have expanded approval for GSK's RSV vaccine in this at increased risk population |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
